Cost-Effectiveness and Cost-Utility Analysis of Cinnarizine Compared to Valproate in Pediatric Migraine: An Iranian Perspective.

Cinnarizine and Valproate are medications used to prevent migraines in children. This study compared the cost-effectiveness of these two treatments. It involved 150 children aged 5 to 17 years in Shiraz, Iran. The children received either Cinnarizine or Valproate for three months. Researchers measured how often migraines occurred and the quality of life. They used decision-tree models to analyze costs and benefits. The study collected data from medical records and questionnaires. It also considered both direct and indirect costs associated with treatments. Results showed that Cinnarizine may offer better value for money. This is important for families and healthcare providers making treatment choices. Understanding the cost-effectiveness can help improve care for children suffering from migraines. Overall, the findings suggest that Cinnarizine could be a preferred option for managing pediatric migraines in Iran. Clinical relevance: This study indicates that Cinnarizine may be a more cost-effective option for treating childhood migraines compared to Valproate, potentially improving treatment choices for clinicians and patients.